{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-004116","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2026-05-19T20:05:46+00:00","discovered_at":"2026-05-19T20:07:00.260475+00:00","generated_at":"2026-05-19T21:32:21.274943+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sunshine Biopharma closes $6.0M public offering with up to $12M additional warrant proceeds","bullets":["Gross proceeds $6.0M from 12,000,000 units at $0.50/unit; closed May 19, 2026.","Each unit includes one share (or pre-funded warrant) plus two Series C warrants exercisable at $0.50 for five years.","Potential additional $12.0M if Series C warrants fully exercised; no assurance given.","Net proceeds for general corporate purposes and working capital.","Aegis Capital Corp acted as placement agent with 7% fee plus 2% expense allowance."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004116","json":"https://secwatch.observer/filing/0001683168-26-004116.json","markdown":"https://secwatch.observer/filing/0001683168-26-004116.md","text":"https://secwatch.observer/filing/0001683168-26-004116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/0001683168-26-004116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:32:21.274943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc5a13c019fe31260f836f7ae9ea6a45ed500d2a","claim":"Sunshine Biopharma Inc. entered into Placement Agent Agreement with Aegis Capital Corp. valued at approximately $6 million (effective 2026-05-18).","evidence_excerpt":"On May 18, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/0001683168-26-004116-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Aegis Capital Corp."},{"label":"Value","value":"approximately $6 million"},{"label":"Effective","value":"2026-05-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}